# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093238
Filing Date
2024-08-08
Accepted
2024-08-08 06:19:33
Documents
63
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | ck0001991792-20240630.htm iXBRL | 10-Q | 1594246
2 | EX-31.1 | ck0001991792-ex31_1.htm | EX-31.1 | 14605
3 | EX-31.2 | ck0001991792-ex31_2.htm | EX-31.2 | 14411
4 | EX-32.1 | ck0001991792-ex32_1.htm | EX-32.1 | 8806
5 | EX-32.2 | ck0001991792-ex32_2.htm | EX-32.2 | 8881
| Complete submission text file | 0000950170-24-093238.txt |  | 6212286

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | ck0001991792-20240630.xsd | EX-101.SCH | 925214
66 | EXTRACTED XBRL INSTANCE DOCUMENT | ck0001991792-20240630_htm.xml | XML | 923107

Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41925 | Film No.: 241185867
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)